Navigation Links
Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions in Serum Triglycerides in Preclinical Testing
Date:6/2/2011

BETHESDA, Md., June 2, 2011 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEXD) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia.

SPX-106 is one of five small molecules licensed by Spherix last year.  In early 2011, Spherix initiated the preclinical development of SPX-106 and D-tagatose as a treatment for hypertriglyceridemia.  In the recently completed study, treatment of animals using combination therapy with twice-daily oral dosing significantly reduced triglycerides by 43 mg/dl compared with control animals with a mean triglyceride level of 118 mg/dl (p=0.01).  The same therapy significantly reduced total cholesterol by 73 mg/dl from a mean level of 378 mg/dl compared with control animals (p=0.01).

SPX-106 is in preclinical development in combination with other agents, including D-tagatose, for the prevention and treatment of atherosclerosis, hypertriglyceridemia and related dyslipidemias.  The Company has initiated development of SPX-106 and D-tagatose as a treatment for hypertriglyceridemia, and plans to start an initial human efficacy study in the fourth quarter of 2011 or the first quarter of 2012.

"Spherix has toxicology, preclinical, clinical and other studies underway, and the findings of this preclinical study advance our understanding of the effects of SPX-106 and D-tagatose on triglycerides and cholesterol," said Dr. Claire Kruger, Chief Executive Officer of Spherix. "The market for triglyceride-lowering drugs exceeds $3 billion annually in the U.S. alone, and we believe that, should our studies be successful, there will be an important role for SPX-106 to play in the treatment regimen."

In December 2010, the Company signed a research contract with a leading global contract research organization (CRO) to investigate the role of SPX-106 and D-tagatose in lowering triglycerides.  Work will continue through at least 2012.  In the first phase of this program, the Company is working with the CRO to design and execute studies in cell culture, animal models and humans to clarify the mechanism of action of SPX-106 and D-tagatose in modulating triglycerides in the metabolic syndrome.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis.  Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction and stroke.  Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherix Announces Registered Direct Offering of $2.77 Million
2. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
3. Spherix Announces Third Quarter 2010 Financial Results
4. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
5. Spherix Announces Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants
6. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
7. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
8. Spherix Reports Third Quarter 2009 Earnings
9. Spherix Announces Positive Phase 2 Study Results
10. Spherix Reports First Quarter 2009 Earnings
11. Spherix Elects New Independent Director, and Elects Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president ... today. In his new role, Marziani will lead the company,s business development and sales ... improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... 2016 , ... Jericho Project has named LaToya Williams-Belfort to the position of ... fundraising and communications for the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and ... homelessness at its roots. , “LaToya Williams-Belfort is joining Jericho at an exciting ...
(Date:5/24/2016)... ... May 24, 2016 , ... Local engineering firm, ... Virginia Medical Center located in Woodbridge, VA. The project includes a brand ... single site. , The new 2 story building houses the Central Sterile department, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed by ongoing ... therapy technology, protocols and patient results as have been achieved with Okyanos Cell ... accessible standard of care for patients worldwide. , As the Medical Advisory Chairman at ...
(Date:5/24/2016)... ... May 24, 2016 , ... Boyd Industries, a leading supplier of ... groundbreaking new product for pediatric dentistry , at AAPD 2016, the annual conference ... May 26-29. The Concealed Delivery Unit keeps dental hand pieces and other anxiety-provoking pieces ...
(Date:5/24/2016)... ... May 24, 2016 , ... Growing in popularity, more and more people ... are available and easily accessible. Whether someone chooses to cut gluten out of their ... diet, King Kullen Grocery stocks their shelves with many different gluten-free products all year ...
Breaking Medicine News(10 mins):